- Home
- RRC vs LEGN Comparison
RRC vs LEGN Comparison
Compare RRC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RRC | LEGN |
|---|---|---|
| Founded | 1976 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | RRC | LEGN |
|---|---|---|
| Price | $35.16 | $22.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | $42.06 | ★ $69.58 |
| AVG Volume (30 Days) | ★ 3.3M | 2.3M |
| Earning Date | 10-28-2025 | 11-12-2025 |
| Dividend Yield | ★ 1.02% | N/A |
| EPS Growth | ★ 19.84 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $2,891,506,000.00 | $909,045,000.00 |
| Revenue This Year | $27.78 | $68.52 |
| Revenue Next Year | $12.14 | $48.63 |
| P/E Ratio | $14.86 | ★ N/A |
| Revenue Growth | 24.57 | ★ 74.75 |
| 52 Week Low | $30.32 | $21.19 |
| 52 Week High | $43.50 | $45.30 |
Technical Indicators
Market Signals| Indicator | RRC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 33.52 |
| Support Level | $34.27 | $21.19 |
| Resistance Level | $36.05 | $23.24 |
| Average True Range (ATR) | 0.95 | 1.04 |
| MACD | -0.17 | 0.18 |
| Stochastic Oscillator | 26.45 | 21.26 |
Price Performance
Historical ComparisonAbout RRC Range Resources Corporation
Fort Worth-based Range Resources is an independent exploration and production company with that focuses entirely on its operations in the Marcellus Shale in Pennsylvania. At year-end 2024, Range Resources' proven reserves totaled 18.1 trillion cubic feet equivalent, with net production of 2.18 billion cubic feet equivalent per day. Natural gas accounted for 68% of production.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.